Record number:
923
Adverse Occurrence type:
MPHO Type:
Estimated frequency:
Most recent risk assessment for pineocytoma and pineoblastoma (Council of Europe, 2022):
Organs from potential donors with pineocytomas (WHO grade I) may be considered minimal risk for transmission. Organs from potential donors with pineoblastomas (WHO grade IV) are considered intermediate to high risk, depending on the different international recommendations, which will be adjusted with increasing evidence. Parenchymal tumours of indeterminate differentiation (WHO grade II or III) without any risk factors should be accepted according to WHO grade III if differentiation cannot definitely be assigned. The transmission risk is increased (high risk) in cases with previous interventions such as tumour resection, -ventriculo-peritoneal/-atrial drainage and/or cranial chemo-/radiotherapy.
Time to detection:
4 months
Alerting signals, symptoms, evidence of occurrence:
Rapidly growing mass in right mandible. Biopsy reveals a malignant small round blue cell tumor with the immunohitochemistry profile of a Primary Neuroectodermic Tumor (PNET). Staging evaluation reveales the tumor in the right mandible with bone marrow involvement.
Demonstration of imputability or root cause:
Condition present in the donor (autopsy results available seven weeks after transplantation, which found a pineoblastoma with meningeal spread. Recipient's tumor and donor's pineoblastoma share the same immunophenotype and HLA type.
Keywords:
Suggest references:
aaa